Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07767175
PHASE1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Official title: A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

142

Start Date

2026-08-12

Completion Date

2027-09-23

Last Updated

2026-09-04

Healthy Volunteers

Yes

Interventions

DRUG

NNC0721-8060

NNC0721-8060 will be administered subcutaneously.

DRUG

Semaglutide

Semaglutide will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Locations (2)

ICON Early Phase Services, LLC

Lenexa, Kansas, United States

ICON

San Antonio, Texas, United States